Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 368506
US Patent granted November 2004, #6,818,619 – Chimeric natriuretic peptides
CD-NP is a rationally-designed synthetic peptide developed to incorporate the optimal components of naturally occurring natriuretic peptides. CD-NP is a selective NPRB agonist that has shown potent renal enhancement and cardiac unloading properties in vivo. Importantly, however, CD-NP appears to do so with minimal hypotensive effects as compared with competitive products. In multiple preclinical studies, including a large animal model of congestive heart failure, CD-NP demonstrated potent therapeutic activity.
IPSCIO Record ID: 203275
CU-NP is a natriuretic peptide that consists of amino acid chains identical to those produced by the human body, specifically the ring structure of C-type natriuretic peptide, or CNP, and the N- and C-termini of Urodilatin, or URO, which exhibits cardiac unloading actions while minimizing the blood pressure lowering effects of CNP and augmenting the physiological effects of natriuresis.
CU-NP have shown it to
Increase the release of sodium by increasing elimination (via urine)
Increase glomerular filtration rate (a measure of kidney function) in a dose dependent manner
Decrease pressures in the heart
Regulate the fluid balance in the body without significantly reducing blood pressure
IPSCIO Record ID: 279319
Drug means the hybrid natriuretic peptides (CD-NP) known as cenderitide as defined in US Patent Number(s) 6,407,211 owned or licensed or otherwise acquired by or assigned to Nile, which exist at the Effective Date.
Cenderitide, our lead product candidate, is a chimeric natriuretic peptide that we are developing for the treatment of heart failure.
6,407,211 – Chimeric natriuretic peptides
Licensee Patents focus on the use of hybrid natriuretic peptides, including but not limited to CD-NP, as defined.
Licensee Patents means the following Intellectual Property
6,818,619 – Chimeric natriuretic peptides
7,384,917 – Chimeric natriuretic peptides
Intellectual Property means all forms of intellectual property in any jurisdiction and under any law, whether now or hereafter existing, including (a) inventions, discoveries, patent applications, patents (including letters patent, industrial designs, and inventorâ€™s certificates), design registrations, invention disclosures, and applications to register industrial designs, and any and all rights to any of the foregoing anywhere in the world, including any provisionals, substitutions, extensions, supplementary patent certificates, reissues, re-exams, renewals, divisions, continuations, continuations in part, continued prosecution applications, and other similar filings or notices provided for under the laws of the United States, or of any other country; (b) trade secrets and other confidential or non-public business information, including ideas, formulas, compositions, inventorâ€™s notes, discoveries, improvements, concepts, know-how, manufacturing and production processes and techniques, testing information, research and development information, data resulting or derived from research activities, inventions, invention disclosures, unpatented blue prints, drawings, specifications designs, plans, proposals and technical data, business and marketing plans, market surveys, market know-how and customer lists and related information; (c) copyrights, whether or not registered, and any non-registered copyright to any writings and other copyrightable works of authorship, including source code, object code, documentation (whether or not released), and databases; (d) features of shape, configuration, pattern or ornament; and (e) registrations of, and applications to register, any of the foregoing with any governmental entity and any renewals or extensions thereof and all other rights to any of the foregoing.
Clinical Study means the Phase IIa feasibility study designed by Nile to be conducted hereunder as further set forth in this agreement.
IPSCIO Record ID: 7466
IPSCIO Record ID: 240469
The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.
IPSCIO Record ID: 204350
Trademark means the Natrecor(R) trademark. The Active Pharmaceutical Ingredient means NatrecorÂ®. NatrecorÂ® means nesiritide or B-type natriuretic peptide (BNP) the amino acid sequence.
Nesiritide (Natrecor) is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the reninâ€“angiotensinâ€“aldosterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation. Neseritide was believed initially to be beneficial for acute decompensated congestive heart failure.